



HAL
open science

Prevalence of hypothyroidism in Finland—a nationwide prescription study

Lauri J. Virta, Seija I. Eskelinen

► **To cite this version:**

Lauri J. Virta, Seija I. Eskelinen. Prevalence of hypothyroidism in Finland—a nationwide prescription study. *European Journal of Clinical Pharmacology*, 2010, 67 (1), pp.73-77. 10.1007/s00228-010-0884-4. hal-00617917

HAL Id: hal-00617917

<https://hal.science/hal-00617917>

Submitted on 31 Aug 2011

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Prevalence of hypothyroidism in Finland - a nationwide prescription study

Journal:	<i>European Journal of Clinical Pharmacology</i>
Manuscript ID:	EJCP-2010-0122.R1
Type of submission:	Original
Date Submitted by the Author:	29-Jun-2010
Complete List of Authors:	Virta, Lauri; The Social Insurance Institution, Research Department Eskelinen, Seija; University of Turku, Family Medicine; Pori Health Center

1
2
3
4 **Prevalence of hypothyroidism in Finland - a nationwide prescription**
5
6 **study**
7
8
9

10
11
12
13
14 **Lauri J Virta · Seija I Eskelinen**
15
16

17
18
19
20
21 L. Virta

22 The Social Insurance Institution, Research Department,
23
24 Turku, Finland
25
26

27
28 S. Eskelinen

29 Pori Health Center, Pori, Finland

30
31 Address for corresponding:

32 Department of Family Medicine, University of Turku

33 Lemminkäisenkatu 1

34 20014 Turku, Finland

35 e-mail seiesk@utu.fi

36 Tel: +358 40072275

37 Fax: +358 23338439
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Purpose The aim of this study was to estimate the one-year prevalence of levothyroxine-treated hypothyroidism in Finland.

Methods From the nationwide Finnish Drug Prescription Database we retrieved all individuals who had regularly purchased the levothyroxine medication during the year 2007. The prevalence rates and 95% CIs were calculated per 100 persons assuming a Poisson distribution.

Results Altogether, 189,027 persons (female 84%) used levothyroxine tablets and, hence, the one-year prevalence of hypothyroidism was 3.6%. The disease was notably more common in females (5.9%) than in males (1.2%); the gender prevalence rate ratio (PRR) was 4.5. Prevalence increased with age. Regionally, between five university hospitals districts the prevalence rates were fairly stable, the lowest rate was 3.1% and the highest 4.4%, regional PRR was 1.3.

Conclusions To the best of our knowledge, this nationwide prescription study deals with the largest population of reported levothyroxine users to date. This comprehensive data justifies estimating the gender- and age-specific prevalence of hypothyroidism in Finland.

Keywords Drug therapy • Finland • Hypothyroidism • Levothyroxine treatment • Pharmacoepidemiology • Prevalence • Registries

Introduction

Hypothyroidism is the most common pathological hormone deficiency, and levothyroxine is the treatment of choice. In patients with primary hypothyroidism dysfunction is in the level of thyroid gland and serum thyrotropin (TSH) is elevated. In patients with central, also secondary hypothyroidism, the TSH level is low or low-normal [1]. Controversy [2] in the diagnosis and treatment of subclinical (biochemical) hypothyroidism, defined as mildly elevated TSH with normal free thyroid hormone values and questionable symptoms, may affect the prevalence rates of hypothyroidism nationally or even regionally.

Because primary hypothyroidism is much more frequent (95%) than secondary hypothyroidism (5%), the concentration of TSH above the normal range has been used to estimate the prevalence of hypothyroidism in the United States, resulting in prevalence rates ranging from 4.6% (0.3% clinical and 4.3% subclinical) [3] to 9.5% (0.4% clinical and 9.0% subclinical) [4]. However, conclusions based on a single laboratory measurement are a well-known problem and the TSH measurement should be carried out in the morning, which decreases the participation rate. Some of the studies on the prevalence of hypothyroidism are based on estimates from diverse clinical populations or questionnaires with uncertain self-reported diseases.

There are no previous studies on the prevalence of hypothyroidism in Finland. In other Nordic Countries, the prevalence of hypothyroidism has been studied mostly in select age groups in one or a few geographical regions. The only large population-based study from Norway [5] showed that the prevalence of former diagnosed hypothyroidism was 4.8% in females and 0.9% in males.

1
2
3 The purpose of this study was to estimate the one-year prevalence of hypothyroidism
4 in Finland according to regular purchases of levothyroxine by analyzing data from a
5 comprehensive nationwide Prescription Database. We also wanted to study if there
6 are regional differences in levothyroxine use between university hospital districts.
7
8
9
10
11

12 13 14 15 **Patients and methods**

16
17 Finland has a National Health Insurance Scheme, which covers all residents living in
18 a particular community, and a unique personal social security number is used as
19 identification for each insured person. This code reveals their birth date and gender.
20
21 The expenses of medicinal products prescribed by a physician for treatment of an
22 illness are partially (42% or 72%) or totally (100%) reimbursed by the Social
23 Insurance Institution (SII) of Finland [6].
24
25
26
27
28
29
30
31
32
33

34 Outside institutions, the treatment of hypothyroidism with levothyroxine sodium
35 tablets (0.1 mg or 25 µg) is available by prescription only. The prescriptions are valid
36 for one year from the day on which they were prescribed, but Finnish reimbursement
37 regulations restrict the maximum number of tablets supplied per redemption to cover
38 only a three-month period. Therefore, patients with chronic conditions and in need of
39 daily drug treatment, such as hypothyroidism, generally redeem prescriptions several
40 times (at least 3 discrete purchasing days) during a year, and we considered those
41 patients to be persistent levothyroxine users.
42
43
44
45
46
47
48
49
50
51

52 53 54 55 *Data source and collection*

56
57 All drugs prescribed by physicians to outpatients and reimbursed by the National
58 Health Insurance Scheme are registered in a Finnish Drug Prescription Register,
59
60

1
2
3 established in 1993 and maintained by SII [7]. For defining pharmaceuticals, the
4
5 Anatomical Therapeutic Chemical (ATC) classification system is used [8]. The
6
7
8 register also contains the dispensing date for the prescription, the number of dispensed
9
10 packages and tablets and information on the person's place of residence.
11

12
13
14
15 Previously, before the year 2006, a remarkable number of levothyroxine purchases
16
17 were not reimbursed and, thus, not registered because of the low price of the drug
18
19 (less than 10 Euros per package of 100 levothyroxine tablets). When, at the beginning
20
21 of 2006, the method of calculating reimbursement payments in the Finnish insurance
22
23 system changed, it appeared to be an exceptional opportunity for estimating the
24
25 prevalence of the hypothyroid disease within the general population. With the reform,
26
27 the fixed non-reimbursable sum paid by the patient per purchase (10 Euros) was
28
29 abandoned. In the new system, the reimbursement payment is calculated separately
30
31 for each medical product, and thereby almost every levothyroxine purchase is visible
32
33 in the drug prescription register. According to the wholesale statistics of the National
34
35 Agency for Medicines (NAM), in 2007 the prescription register covered 95.7% of
36
37 total levothyroxine sodium consumption (in DDDs) in Finnish outpatient care (Tinna
38
39 Voipio, NAM, personal communication).
40
41
42
43
44
45
46
47

48 From the nationwide drug prescription register, we retrieved all individuals who, from
49
50 1 January 2006 to 31 December 2008, purchased medicines belonging to ATC-code
51
52 H03AA01. In 2007, altogether 192,927 outpatients redeemed at least one prescription
53
54 of levothyroxine. The final study data here consists of those patients who redeemed
55
56 their levothyroxine prescriptions during at least 3 discrete days; either during the year
57
58 2007 or by also making their purchases in the years 2006 and/or 2008.
59
60

1
2
3
4
5
6 The prevalence rates of hypothyroidism were calculated by dividing the number of
7
8 patients purchasing levothyroxine in the year 2007 as nominator by the population at
9
10 risk (per 100 persons) as denominator. The group at risk consisted of the whole
11
12 Finnish population at the end of 2007 (5.30 million) [9] – excluding 24,810 persons
13
14 residing year-round (2007) in a public nursing home or hospital [10].
15
16
17
18

19 20 *Statistics*

21
22 The 95% confidence intervals (95% CI) for the prevalence rates were calculated
23
24 assuming a Poisson distribution. A Poisson regression model was used to adjust the
25
26 rates for gender or age (categorized as 0–19, 20–29, 30–39, 40–49, 50–59, 60–69,
27
28 70–79 and >79 years). Comparisons were further made between the five university
29
30 hospital districts in Finland (Table 2). The statistical significance of the relationships
31
32 of prevalent cases based on gender or area was quantified by calculating the
33
34 prevalence rate ratio (PRR) with a 95% CI. P-values less than 0.05 were considered to
35
36 be statistically significant. Statistical computation was performed using the
37
38 GENMOD procedure in the SAS system for Windows, version 9.1/2004.
39
40
41
42
43
44
45
46
47
48
49

50 51 *Ethical considerations*

52
53 Ethical approval was not necessary, since we analysed only encrypted register data
54
55 and did not contact the unidentifiable study subjects.
56
57
58

59 60 **Results**

1
2
3 In the year 2007, altogether 189,027 outpatients (female 84%) regularly used
4
5 levothyroxine in Finland. This places the nationwide prevalence of drug-treated
6
7 hypothyroidism at 3.6% (95 % CI: 3.57 to 3.60). The disease was notably more
8
9 common in females (5.9%) than in males (1.2%) (Table 1); the gender PRR was 4.5
10
11 (95 % CI: 4.48–4.59), $p < 0.001$, after adjusting for age.
12
13
14
15
16

17 Table 1 here
18
19
20
21

22 The mean age of stable thyroxine users was 61.3 (SD 16.3) years; 43% of the patients
23
24 were older than 64 years and 56% were at working age (16–64 years). The highest
25
26 prevalence rate, 11.0%, was seen in the oldest age group (over 79 years), and the
27
28 prevalence rate peaked in males at the age of 98 years (9.4%) and in females at the
29
30 age of 75 years (14.2%). Within all age groups, the prevalence rates differed
31
32 significantly between gender, the difference was greatest in the age group 30–39
33
34 (Table 1).
35
36
37
38
39
40

41 Regional prevalence figures varied slightly (Table 2). The highest prevalence rate
42
43 (4.4%) was seen in the university hospital district of Turku and the lowest (3.1%) in
44
45 the Helsinki district (the district adjacent to Turku); the regional PRR was 1.3 (95%
46
47 CI: 1.25–1.29), $p < 0.001$, after adjusting for age and gender. In the southern and
48
49 western parts of Finland (the districts of Helsinki, Turku and Tampere) the prevalence
50
51 rate was 3.5%, whereas in the eastern and northern parts of Finland (the districts of
52
53 Kuopio and Oulu) it was 3.8%; this regional PRR was only barely significant, 1.06
54
55 (95% CI: 1.05–1.07), $p < 0.001$, after adjusting for age and gender.
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 2 here

The median daily consumption of levothyroxine was 92.3 µg (mean 92.6 + 40.0 µg per day; 103.1 in males and 90.5 in females). The mean daily dosages were associated with the patients' age (Figure 1). There were 26,219 (13.9%) patients with a low daily dose of levothyroxine (less than 51 µg) and 15,971 (8.4%) patients with a high daily dose (more than 150 µg). In the former subgroup the mean age was 64.1 years and women comprised 84.6% of the patients; in the latter subgroup the corresponding figures were 54.8 and 68.5%. Table 3 represents the regional prevalence rates of hypothyroidism among those patients with low daily levothyroxine consumption.

The number of levothyroxine prescriptions redeemed by a patient per year was an average of 3.4 (mean 3.6 + 1.3). The prescriptions collected annually (that is, compliance with levothyroxine treatment) did not differ substantially between daily consumption subgroups: the mean number of prescriptions purchased per year was 3.5 in patients on 51–150 µg daily levothyroxine doses, 3.7 in those on low doses and 3.6 in those on high doses.

Figure 1 here

Table 3 here

Discussion

The definite main indication for levothyroxine use is hypothyroidism, which justified evaluating the prevalence of hypothyroidism based on regular levothyroxine purchases. In this nationwide prescription study, 5.9% of females and 1.2% of males

1
2
3 living outside institutions in Finland received levothyroxine medication in 2007.
4
5
6 There was no clinically significant regional variation in levothyroxine use between
7
8 university hospital districts. Our figures correspond well with previous studies that
9
10 use laborious designs [5,11]. Thus, persistent levothyroxine purchases seem to serve
11
12 as a readily available and apparently successful estimate of the prevalence of
13
14
15 hypothyroidism.
16
17

18
19
20 The pattern of thyroid disorders depends partly on genetic factors, but mostly on the
21
22 level of dietary iodine intake [12]. Finland is generally considered to be a country
23
24 where people have a sufficient intake of iodine [13], as is Scotland, where subjects
25
26 with hypothyroidism were identified by electronic linkages between seven databases
27
28 [11]. Parallel with our figures, the prevalence rates of primary hypothyroidism in that
29
30 British study were 5.1% in females and 0.9% in males in 2001. In central Norway,
31
32 where people also have sufficient iodine intake, a large regional health survey
33
34 between 1995 and 1997 included both questionnaires that asked all participants (20
35
36 years and older) eight thyroid-related questions and thyroid blood tests from specific
37
38 age groups, with the results showing the prevalence rates of formerly-diagnosed
39
40 hypothyroidism to be 4.8% in women and 0.9% in men [5]. The prevalence of
41
42 hypothyroidism increased with age among both men and women. Also in line with
43
44 our study, smaller studies among elderly Nordic subjects confirm the increasing
45
46 prevalence of hypothyroidism with age, especially in women [12, 14, 15].
47
48
49
50
51
52
53

54
55 The U.S. diet is also acknowledged as being sufficient in iodine. The Framingham
56
57 Study showed that 13.6% of American women older than 60 years of age had TSH
58
59
60

1
2
3 levels greater than 5 mIU/L [16]. Of the women older than 74 years of age screened at
4
5 a Colorado health fair, 21% had TSH levels greater than 10 mIU/L [4].
6
7
8
9

10 Because of the limits of the survey based on the prescription database, our results may
11
12 a bit under- or overestimate the true prevalence of hypothyroidism. We could not
13
14 detect the overall amount of undiagnosed or untreated thyroid deficiency within the
15
16 general population. Lack of data on drug use in nursing homes may also cause us to
17
18 underestimate the extent of the problem, especially among the elderly. On the other
19
20 hand, because of the lack of information about indication for the prescriptions, we
21
22 were not able to exclude subjects who suffered from hypothyroidism secondary to
23
24 treatment for other thyroid disorders. Better interpretation of results requires active
25
26 linkage between registries, for example registry of all hospital admissions [17,18].
27
28
29
30
31
32
33

34 However, other indications than primary hypothyroidism for regular levothyroxine
35
36 use are rare. For example, the incidence of thyroid cancer was 91 in men and 282 in
37
38 women in the year 2007 in Finland and the prevalence of patients with treated thyroid
39
40 cancer as of 1 January 2008 was 1,263 in men and 5,440 in women [18]. Excluding
41
42 them afterwards from our calculations of the prevalence of hypothyroidism does not
43
44 change our figures. Our nationwide study also included children with rare (1:4000
45
46 live births) congenital hypothyroidism [19]. National cord blood screening for
47
48 congenital hypothyroidism has been done throughout all of Finland since 1980 [20].
49
50
51
52
53
54

55 Low levothyroxine dosage can be a sign of the treatment of subclinical
56
57 hypothyroidism [2, 21]. Low daily dosages of levothyroxine did not differ markedly
58
59 between university hospital districts. The optimum dose of levothyroxine when
60

1
2
3 treating overt hypothyroidism is related to bodyweight, about 1.8 μg per kg per day in
4
5 adults with a benign thyroid disease [22], and age, with a dose requirement that is
6
7 higher in infants and young children and is lower in older adults. The curve for the
8
9 mean daily levothyroxine dosage by age in our population logically has the shape of
10
11 an inverted U. A regular daily dosage of 50 μg or lower in a working-age patient may
12
13 also be an indicator of inadequate treatment. About 20 % of patients are receiving an
14
15 inadequate levothyroxine dose for overt hypothyroidism in previous studies [4, 23].
16
17
18
19

20
21
22 Compliance with levothyroxine treatment is expected to be high because
23
24 levothyroxine does not have any side effects if the dosage is correct. We used data on
25
26 medication retrieved from the pharmacy rather than medications prescribed by
27
28 physicians, thus avoiding primary noncompliance [24].
29
30
31
32
33

34 In Western countries, an increasingly older female population increases also the
35
36 prevalence of hypothyroidism and its impact on the resources used in primary care,
37
38 where hypothyroidism is mainly managed. The size and nature (including only
39
40 patients who are actually being treated) of the comprehensive nationwide prescription
41
42 database with the elimination of recall and selection bias provides a unique potential
43
44 for pharmacoepidemiological studies among large populations.
45
46
47
48
49

50 References

- 51 1. Roberts CG, Ladenson PW (2004) Hypothyroidism. *Lancet* 363:793-803.
- 52 2. Surks M, Ortiz E, Daniel G et al (2004) Subclinical thyroid disease: scientific
53 review and guidelines for diagnosis and management. *JAMA* 291:228-38.
- 54 3. Hollowell J, Staehling N, Flanders W et al (2002) Serum TSH, T₄, and thyroid
55 antibodies in the United States population (1988 to 1994): National Health and
56
57
58
59
60

- 1
2
3 Nutrition Examination Survey (NHANES III). *J Clin Endocrinol Metab*
4 87:489-99.
5
6
7 4. Canaris G, Manowitz N, Mayor G, Ridgway E (2000) The Colorado thyroid
8 disease prevalence study. *Arch Intern Med* 160:526-34.
9
10 5. Bjoro T, Holmen J, Kruger O et al (2000) Prevalence of thyroid disease,
11 thyroid dysfunction and thyroid peroxidase antibodies in a large, unselected
12 population. The Health Study of Nord-Trondelag (HUNT). *Eur J Endocrinol*
13 143:639-47.
14
15 6. National Agency for Medicines and Social Insurance Institution (2008)
16 Finnish Statistics on Medicines 2007. Helsinki.
17
18 7. Furu K, Wettermark B, Andersen M, Martikainen J, Almarsdottir A, Sorensen
19 H (2010) The Nordic countries as a cohort for pharmacoepidemiological
20 research. *Basic Clin Pharmacol Toxicol.* 106:86-94.
21
22 8. <http://www.whocc.no/atcddd/>. Accessed 5 Feb, 2010
23
24 9. Statistics Finland (2007) Population structure. <http://www.stat.fi>
25
26 10. National Institution for Health and Welfare (THL), statistics and registers,
27 SOTKANet. <http://www.thl.fi>.
28
29 11. Leese G, Flynn R, Jung R, MacDonald T, Murphy M, Morris A (2008)
30 Increasing prevalence and incidence of thyroid disease in Tayside, Scotland:
31 the Thyroid Epidemiology Audit and Research Study (TEARS). *Clin*
32 *Endocrinol (Oxf)*. 68:311-6.
33
34 12. Laurberg P, Pedersen K, Hreidarsson A, Sigfusson N, Iversen E, Knudsen P
35 (1998) Iodine intake and the pattern of thyroid disorders: a comparative
36 epidemiological study of thyroid abnormalities in the elderly in Iceland and in
37 Jutland, Denmark. *J Clin Endocrinol Metab* 83:765-9.
38
39 13. Delange F (2002) Iodine deficiency in Europe and its consequences: an
40 update. *Eur J Nucl Med Mol Imaging* 29:S404-16.
41
42 14. Sundbeck G, Lundberg P, Lindstedt G, Jagenburg R, Eden S (1991) Incidence
43 and prevalence of thyroid disease in elderly women: results from the
44 longitudinal population study of elderly people in Gothenburg, Sweden. *Age*
45 *Ageing* 20:291-8.
46
47 15. Petersen K, Lindstedt G, Lundberg P, Bengtsson C, Lapidus L, Nyström E
48 (1991) Thyroid disease in middle-aged and elderly Swedish women: thyroid-
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 related hormones, thyroid dysfunction and goitre in relation to age and
4 smoking. *J Intern Med* 229:407-13.
5
6
7 16. Sawin C, Castelli W, Hersman J, McNamara P, Bacharach P (1985) The aging
8 thyroid. Thyroid deficiency in the Framingham Study. *Arch Intern Med*
9 145:1386-8.
10
11
12 17. National Institution for Health and Welfare (THL), statistics and registers,
13 health services. <http://www.thl.fi>.
14
15
16 18. Finnish Cancer Registry, Cancer Statistics. www.cancerregistry.fi, updated on
17 03.02.2010.
18
19 19. LaFranchi, S (1999) Congenital hypothyroidism: etiologies, diagnosis, and
20 management. *Thyroid* 9:735-40.
21
22
23 20. Virtanen M, Perheentupa J, Mäenpää J, Pitkänen L, Pikkarainen J (1984)
24 Finnish national screening for hypothyroidism. Few false positives, early
25 therapy. *Eur J Pediatr* 143:2-5.
26
27
28 21. Villar H, Saconato H, Valente O, Atallah A (2007) Thyroid hormone
29 replacement for subclinical hypothyroidism. *Cochrane Database Syst Rev*
30 CD003419.
31
32
33 22. Fish L, Schwartz H, Cavanaugh J, Steffes M, Bantle J, Oppenheimer J (1987)
34 Replacement dose, metabolism, and bioavailability of levothyroxine in the
35 treatment of hypothyroidism. Role of triiodothyronine in pituitary feedback in
36 humans. *N Engl J Med* 316:764-70.
37
38
39 23. Ross D, Daniels G, Gouveia D (1990) The use and limitations of a
40 chemiluminescent thyrotropin assay as a single thyroid function test in an out-
41 patient endocrine clinic. *J Clin Endocrinol Metab* 71:764-9.
42
43
44 24. Beardon P, McGilchrist M, McKendrick A, McDevitt D, MacDonald T (1993)
45 Primary non-compliance with prescribed medication in primary care. *BMJ*
46 307:846-8.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table captions:

Table 1 Number of cases and prevalence (per 100 persons in the year 2007) of levothyroxine-treated hypothyroidism by gender and age groups.


Table 2 Number of cases and one-year (in 2007) prevalence rates (%) of levothyroxine-treated hypothyroidism by university hospital district in Finland.

Table 3 Number of cases and one-year (in 2007) prevalence rates (%) of low levothyroxine daily dosage (<51 µg) users by university hospital district in Finland.

Figure captions:

Fig. 1 Mean daily dosages (µg /d) of levothyroxine treatment during 2007 by gender and age groups.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Mean daily dosages ($\mu\text{g/d}$) of levothyroxine treatment during 2007 by gender and age groups.
121x80mm (600 x 600 DPI)

Review

1
2
3
4 **Prevalence of hypothyroidism in Finland - a nationwide prescription**
5
6 **study**
7
8
9

10
11
12
13 **Lauri J Virta · Seija I Eskelinen**
14
15

16
17
18
19
20
21 L. Virta

22 The Social Insurance Institution, Research Department,
23
24 Turku, Finland
25
26

27
28 S. Eskelinen

29 Pori Health Center, Pori, Finland

30
31 Address for corresponding:

32 Department of Family Medicine, University of Turku

33 Lemminkäisenkatu 1

34 20014 Turku, Finland

35 e-mail seiesk@utu.fi

36
37 Tel: +358 40072275

38
39 Fax: +358 23338439
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Purpose The aim of this study was to estimate the one-year prevalence of levothyroxine-treated hypothyroidism in Finland.

Methods From the nationwide Finnish Drug Prescription Database we retrieved all individuals who had regularly purchased the levothyroxine medication during the year 2007. The prevalence rates and 95% CIs were calculated per 100 persons assuming a Poisson distribution.

Results Altogether, 189,027 persons (female 84%) used levothyroxine tablets and, hence, the one-year prevalence of hypothyroidism was 3.6%. The disease was notably more common in females (5.9%) than in males (1.2%); the gender prevalence rate ratio (PRR) was 4.5. Prevalence increased with age. Regionally, between five university hospitals districts the prevalence rates were fairly stable, the lowest rate was 3.1% and the highest 4.4%, regional PRR was 1.3.

Conclusions To the best of our knowledge, this nationwide prescription study deals with the largest population of reported levothyroxine users to date. This comprehensive data justifies estimating the gender- and age-specific prevalence of hypothyroidism in Finland.

Keywords Drug therapy • Finland • Hypothyroidism • Levothyroxine treatment • Pharmacoepidemiology • Prevalence • Registries

Introduction

Hypothyroidism is the most common pathological hormone deficiency, and levothyroxine is the treatment of choice. In patients with primary hypothyroidism dysfunction is in the level of thyroid gland and serum thyrotropin (TSH) is elevated. In patients with central, also secondary hypothyroidism, the TSH level is low or low-normal [1]. Controversy [2] in the diagnosis and treatment of subclinical (biochemical) hypothyroidism, defined as mildly elevated TSH with normal free thyroid hormone values and questionable symptoms, may affect the prevalence rates of hypothyroidism nationally or even regionally.

Because primary hypothyroidism is much more frequent (95%) than secondary hypothyroidism (5%), the concentration of TSH above the normal range has been used to estimate the prevalence of hypothyroidism in the United States, resulting in prevalence rates ranging from 4.6% (0.3% clinical and 4.3% subclinical) [3] to 9.5% (0.4% clinical and 9.0% subclinical) [4]. However, conclusions based on a single laboratory measurement are a well-known problem and the TSH measurement should be carried out in the morning, which decreases the participation rate. Some of the studies on the prevalence of hypothyroidism are based on estimates from diverse clinical populations or questionnaires with uncertain self-reported diseases.

There are no previous studies on the prevalence of hypothyroidism in Finland. In other Nordic Countries, the prevalence of hypothyroidism has been studied mostly in select age groups in one or a few geographical regions. The only large population-based study from Norway [5] showed that the prevalence of former diagnosed hypothyroidism was 4.8% in females and 0.9% in males.

1
2
3 The purpose of this study was to estimate the one-year prevalence of hypothyroidism
4 in Finland according to regular purchases of levothyroxine by analyzing data from a
5 comprehensive nationwide Prescription Database. We also wanted to study if there
6 are regional differences in levothyroxine use between university hospital districts.
7
8
9

10 11 12 13 14 15 **Patients and methods**

16
17 Finland has a National Health Insurance Scheme, which covers all residents living in
18 a particular community, and a unique personal social security number is used as
19 identification for each insured person. This code reveals their birth date and gender.
20
21 The expenses of medicinal products prescribed by a physician for treatment of an
22 illness are partially (42% or 72%) or totally (100%) reimbursed by the Social
23 Insurance Institution (SII) of Finland [6].
24
25
26
27
28
29
30
31
32
33

34 Outside institutions, the treatment of hypothyroidism with levothyroxine sodium
35 tablets (0.1 mg or 25 µg) is available by prescription only. The prescriptions are valid
36 for one year from the day on which they were prescribed, but Finnish reimbursement
37 regulations restrict the maximum number of tablets supplied per redemption to cover
38 only a three-month period. Therefore, patients with chronic conditions and in need of
39 daily drug treatment, such as hypothyroidism, generally redeem prescriptions several
40 times (at least 3 discrete purchasing days) during a year, and we considered those
41 patients to be persistent levothyroxine users.
42
43
44
45
46
47
48
49
50
51
52

53 54 55 *Data source and collection*

56
57 All drugs prescribed by physicians to outpatients and reimbursed by the National
58 Health Insurance Scheme are registered in a Finnish Drug Prescription Register,
59
60

1
2
3 established in 1993 and maintained by SII [7]. For defining pharmaceuticals, the
4
5 Anatomical Therapeutic Chemical (ATC) classification system is used [8]. The
6
7
8 register also contains the dispensing date for the prescription, the number of dispensed
9
10 packages and tablets and information on the person's place of residence.
11

12
13
14
15 Previously, before the year 2006, a remarkable number of levothyroxine purchases
16
17 were not reimbursed and, thus, not registered because of the low price of the drug
18
19 (less than 10 Euros per package of 100 levothyroxine tablets). When, at the beginning
20
21 of 2006, the method of calculating reimbursement payments in the Finnish insurance
22
23 system changed, it appeared to be an exceptional opportunity for estimating the
24
25 prevalence of the hypothyroid disease within the general population. With the reform,
26
27 the fixed non-reimbursable sum paid by the patient per purchase (10 Euros) was
28
29 abandoned. In the new system, the reimbursement payment is calculated separately
30
31 for each medical product, and thereby almost every levothyroxine purchase is visible
32
33 in the drug prescription register. According to the wholesale statistics of the National
34
35 Agency for Medicines (NAM), in 2007 the prescription register covered 95.7% of
36
37 total levothyroxine sodium consumption (in DDDs) in Finnish outpatient care (Tinna
38
39 Voipio, NAM, personal communication).
40
41
42
43
44
45
46
47

48 From the nationwide drug prescription register, we retrieved all individuals who, from
49
50 1 January 2006 to 31 December 2008, purchased medicines belonging to ATC-code
51
52 H03AA01. In 2007, altogether 192,927 outpatients redeemed at least one prescription
53
54 of levothyroxine. The final study data here consists of those patients who redeemed
55
56 their levothyroxine prescriptions during at least 3 discrete days; either during the year
57
58 2007 or by also making their purchases in the years 2006 and/or 2008.
59
60

1
2
3
4
5
6 The prevalence rates of hypothyroidism were calculated by dividing the number of
7
8 patients purchasing levothyroxine in the year 2007 as nominator by the population at
9
10 risk (per 100 persons) as denominator. The group at risk consisted of the whole
11
12 Finnish population at the end of 2007 (5.30 million) [9] – excluding 24,810 persons
13
14 residing year-round (2007) in a public nursing home or hospital [10].
15
16
17
18
19

20 *Statistics*

21
22 The 95% confidence intervals (95% CI) for the prevalence rates were calculated
23
24 assuming a Poisson distribution. A Poisson regression model was used to adjust the
25
26 rates for gender or age (categorized as 0–19, 20–29, 30–39, 40–49, 50–59, 60–69,
27
28 70–79 and >79 years). Comparisons were further made between the five university
29
30 hospital districts in Finland (Table 2). The statistical significance of the relationships
31
32 of prevalent cases based on gender or area was quantified by calculating the
33
34 prevalence rate ratio (PRR) with a 95% CI. P-values less than 0.05 were considered to
35
36 be statistically significant. Statistical computation was performed using the
37
38 GENMOD procedure in the SAS system for Windows, version 9.1/2004.
39
40
41
42
43
44
45
46
47
48
49

50 *Ethical considerations*

51
52 Ethical approval was not necessary, since we analysed only encrypted register data
53
54 and did not contact the unidentifiable study subjects.
55
56
57
58
59

60 **Results**

1
2
3 In the year 2007, altogether 189,027 outpatients (female 84%) regularly used
4
5 levothyroxine in Finland. This places the nationwide prevalence of drug-treated
6
7 hypothyroidism at 3.6% (95 % CI: 3.57 to 3.60). The disease was notably more
8
9 common in females (5.9%) than in males (1.2%) (Table 1); the gender PRR was 4.5
10
11 (95 % CI: 4.48–4.59), $p < 0.001$, after adjusting for age.
12
13
14
15
16

17 Table 1 here
18
19
20
21

22 The mean age of stable thyroxine users was 61.3 (SD 16.3) years; 43% of the patients
23
24 were older than 64 years and 56% were at working age (16–64 years). The highest
25
26 prevalence rate, 11.0%, was seen in the oldest age group (over 79 years), and the
27
28 prevalence rate peaked in males at the age of 98 years (9.4%) and in females at the
29
30 age of 75 years (14.2%). Within all age groups, the prevalence rates differed
31
32 significantly between gender, the difference was greatest in the age group 30–39
33
34 (Table 1).
35
36
37
38
39
40

41 Regional prevalence figures varied slightly (Table 2). The highest prevalence rate
42
43 (4.4%) was seen in the university hospital district of Turku and the lowest (3.1%) in
44
45 the Helsinki district (the district adjacent to Turku); the regional PRR was 1.3 (95%
46
47 CI: 1.25–1.29), $p < 0.001$, after adjusting for age and gender. In the southern and
48
49 western parts of Finland (the districts of Helsinki, Turku and Tampere) the prevalence
50
51 rate was 3.5%, whereas in the eastern and northern parts of Finland (the districts of
52
53 Kuopio and Oulu) it was 3.8%; this regional PRR was only barely significant, 1.06
54
55 (95% CI: 1.05–1.07), $p < 0.001$, after adjusting for age and gender.
56
57
58
59
60

1
2
3 Table 2 here
4

5
6 The median daily consumption of levothyroxine was 92.3 μg (mean $92.6 \pm 40.0 \mu\text{g}$
7
8 per day; 103.1 in males and 90.5 in females). The mean daily dosages were associated
9
10 with the patients' age (Figure 1). There were 26,219 (13.9%) patients with a low daily
11
12 dose of levothyroxine (less than 51 μg) and 15,971 (8.4%) patients with a high daily
13
14 dose (more than 150 μg). In the former subgroup the mean age was 64.1 years and
15
16 women comprised 84.6% of the patients; in the latter subgroup the corresponding
17
18 figures were 54.8 and 68.5%. Table 3 represents the regional prevalence rates of
19
20 hypothyroidism among those patients with low daily levothyroxine consumption.
21
22
23
24
25
26

27 The number of levothyroxine prescriptions redeemed by a patient per year was an
28
29 average of 3.4 (mean 3.6 ± 1.3). The prescriptions collected annually (that is,
30
31 compliance with levothyroxine treatment) did not differ substantially between daily
32
33 consumption subgroups: the mean number of prescriptions purchased per year was
34
35 3.5 in patients on 51–150 μg daily levothyroxine doses, 3.7 in those on low doses and
36
37 3.6 in those on high doses.
38
39
40
41
42
43
44
45

46 Figure 1 here
47

48 Table 3 here
49
50
51
52

53 Discussion

54
55 The definite main indication for levothyroxine use is hypothyroidism, which justified
56
57 evaluating the prevalence of hypothyroidism based on regular levothyroxine
58
59 purchases. In this nationwide prescription study, 5.9% of females and 1.2% of males
60

1
2
3 living outside institutions in Finland received levothyroxine medication in 2007.
4
5
6 There was no clinically significant regional variation in levothyroxine use between
7
8 university hospital districts. Our figures correspond well with previous studies that
9
10 use laborious designs [5,11]. Thus, persistent levothyroxine purchases seem to serve
11
12 as a readily available and apparently successful estimate of the prevalence of
13
14
15 hypothyroidism.
16
17

18
19
20 The pattern of thyroid disorders depends partly on genetic factors, but mostly on the
21
22 level of dietary iodine intake [12]. Finland is generally considered to be a country
23
24 where people have a sufficient intake of iodine [13], as is Scotland, where subjects
25
26 with hypothyroidism were identified by electronic linkages between seven databases
27
28 [11]. Parallel with our figures, the prevalence rates of primary hypothyroidism in that
29
30 British study were 5.1% in females and 0.9% in males in 2001. In central Norway,
31
32 where people also have sufficient iodine intake, a large regional health survey
33
34 between 1995 and 1997 included both questionnaires that asked all participants (20
35
36 years and older) eight thyroid-related questions and thyroid blood tests from specific
37
38 age groups, with the results showing the prevalence rates of formerly-diagnosed
39
40 hypothyroidism to be 4.8% in women and 0.9% in men [5]. The prevalence of
41
42 hypothyroidism increased with age among both men and women. Also in line with
43
44 our study, smaller studies among elderly Nordic subjects confirm the increasing
45
46 prevalence of hypothyroidism with age, especially in women [12, 14, 15].
47
48
49
50
51
52

53
54
55 The U.S. diet is also acknowledged as being sufficient in iodine. The Framingham
56
57 Study showed that 13.6% of American women older than 60 years of age had TSH
58
59
60

1
2
3 levels greater than 5 mIU/L [16]. Of the women older than 74 years of age screened at
4
5 a Colorado health fair, 21% had TSH levels greater than 10 mIU/L [4].
6
7

8
9
10 Because of the limits of the survey based on the prescription database, our results may
11
12 a bit under- or overestimate the true prevalence of hypothyroidism. We could not
13
14 detect the overall amount of undiagnosed or untreated thyroid deficiency within the
15
16 general population. Lack of data on drug use in nursing homes may also cause us to
17
18 underestimate the extent of the problem, especially among the elderly. On the other
19
20 hand, because of the lack of information about indication for the prescriptions, we
21
22 were not able to exclude subjects who suffered from hypothyroidism secondary to
23
24 treatment for other thyroid disorders. Better interpretation of results requires active
25
26 linkage between registries, for example registry of all hospital admissions [17,18].
27
28
29
30
31
32

33
34 However, other indications than primary hypothyroidism for regular levothyroxine
35
36 use are rare. For example, the incidence of thyroid cancer was 91 in men and 282 in
37
38 women in the year 2007 in Finland and the prevalence of patients with treated thyroid
39
40 cancer as of 1 January 2008 was 1,263 in men and 5,440 in women [18]. Excluding
41
42 them afterwards from our calculations of the prevalence of hypothyroidism does not
43
44 change our figures. Our nationwide study also included children with rare (1:4000
45
46 live births) congenital hypothyroidism [19]. National cord blood screening for
47
48 congenital hypothyroidism has been done throughout all of Finland since 1980 [20].
49
50
51
52

53
54
55 Low levothyroxine dosage can be a sign of the treatment of subclinical
56
57 hypothyroidism [2, 21]. Low daily dosages of levothyroxine did not differ markedly
58
59 between university hospital districts. The optimum dose of levothyroxine when
60

1
2
3 treating overt hypothyroidism is related to bodyweight, about 1.8 μg per kg per day in
4
5 adults with a benign thyroid disease [22], and age, with a dose requirement that is
6
7 higher in infants and young children and is lower in older adults. The curve for the
8
9 mean daily levothyroxine dosage by age in our population logically has the shape of
10
11 an inverted U. A regular daily dosage of 50 μg or lower in a working-age patient may
12
13 also be an indicator of inadequate treatment. About 20 % of patients are receiving an
14
15 inadequate levothyroxine dose for overt hypothyroidism in previous studies [4, 23].
16
17
18
19

20
21
22 Compliance with levothyroxine treatment is expected to be high because
23
24 levothyroxine does not have any side effects if the dosage is correct. We used data on
25
26 medication retrieved from the pharmacy rather than medications prescribed by
27
28 physicians, thus avoiding primary noncompliance [24].
29
30
31
32
33

34 In Western countries, an increasingly older female population increases also the
35
36 prevalence of hypothyroidism and its impact on the resources used in primary care,
37
38 where hypothyroidism is mainly managed. The size and nature (including only
39
40 patients who are actually being treated) of the comprehensive nationwide prescription
41
42 database with the elimination of recall and selection bias provides a unique potential
43
44 for pharmacoepidemiological studies among large populations.
45
46
47
48
49

50 **References**

- 51
52
53 1. Roberts CG, Ladenson PW (2004) Hypothyroidism. *Lancet* 363:793-803.
54
55 2. Surks M, Ortiz E, Daniel G et al (2004) Subclinical thyroid disease: scientific
56
57 review and guidelines for diagnosis and management. *JAMA* 291:228-38.
58
59 3. Hollowell J, Staehling N, Flanders W et al (2002) Serum TSH, T₄, and thyroid
60
antibodies in the United States population (1988 to 1994): National Health and

- 1
2
3 Nutrition Examination Survey (NHANES III). *J Clin Endocrinol Metab*
4 87:489-99.
- 5
6
7 4. Canaris G, Manowitz N, Mayor G, Ridgway E (2000) The Colorado thyroid
8 disease prevalence study. *Arch Intern Med* 160:526-34.
- 9
10 5. Bjoro T, Holmen J, Kruger O et al (2000) Prevalence of thyroid disease,
11 thyroid dysfunction and thyroid peroxidase antibodies in a large, unselected
12 population. The Health Study of Nord-Trondelag (HUNT). *Eur J Endocrinol*
13 143:639-47.
- 14
15
16 6. National Agency for Medicines and Social Insurance Institution (2008)
17 Finnish Statistics on Medicines 2007. Helsinki.
- 18
19
20 7. Furu K, Wettermark B, Andersen M, Martikainen J, Almarsdottir A, Sorensen
21 H (2010) The Nordic countries as a cohort for pharmacoepidemiological
22 research. *Basic Clin Pharmacol Toxicol.* 106:86-94.
- 23
24
25 8. <http://www.whocc.no/atcddd/>. Accessed 5 Feb, 2010
- 26
27
28 9. Statistics Finland (2007) Population structure. <http://www.stat.fi>
- 29
30
31 10. National Institution for Health and Welfare (THL), statistics and registers,
32 SOTKANet. <http://www.thl.fi>.
- 33
34
35 11. Leese G, Flynn R, Jung R, MacDonald T, Murphy M, Morris A (2008)
36 Increasing prevalence and incidence of thyroid disease in Tayside, Scotland:
37 the Thyroid Epidemiology Audit and Research Study (TEARS). *Clin*
38 *Endocrinol (Oxf)*. 68:311-6.
- 39
40
41 12. Laurberg P, Pedersen K, Hreidarsson A, Sigfusson N, Iversen E, Knudsen P
42 (1998) Iodine intake and the pattern of thyroid disorders: a comparative
43 epidemiological study of thyroid abnormalities in the elderly in Iceland and in
44 Jutland, Denmark. *J Clin Endocrinol Metab* 83:765-9.
- 45
46
47 13. Delange F (2002) Iodine deficiency in Europe and its consequences: an
48 update. *Eur J Nucl Med Mol Imaging* 29:S404-16.
- 49
50
51 14. Sundbeck G, Lundberg P, Lindstedt G, Jagenburg R, Eden S (1991) Incidence
52 and prevalence of thyroid disease in elderly women: results from the
53 longitudinal population study of elderly people in Gothenburg, Sweden. *Age*
54 *Ageing* 20:291-8.
- 55
56
57 15. Petersen K, Lindstedt G, Lundberg P, Bengtsson C, Lapidus L, Nyström E
58 (1991) Thyroid disease in middle-aged and elderly Swedish women: thyroid-
59
60

- 1
2
3 related hormones, thyroid dysfunction and goitre in relation to age and
4 smoking. *J Intern Med* 229:407-13.
5
6
7 16. Sawin C, Castelli W, Hersman J, McNamara P, Bacharach P (1985) The aging
8 thyroid. Thyroid deficiency in the Framingham Study. *Arch Intern Med*
9 145:1386-8.
10
11
12 17. National Institution for Health and Welfare (THL), statistics and registers,
13 health services. <http://www.thl.fi>.
14
15
16 18. Finnish Cancer Registry, Cancer Statistics. www.cancerregistry.fi, updated on
17 03.02.2010.
18
19
20 19. LaFranchi, S (1999) Congenital hypothyroidism: etiologies, diagnosis, and
21 management. *Thyroid* 9:735-40.
22
23 20. Virtanen M, Perheentupa J, Mäenpää J, Pitkänen L, Pikkarainen J (1984)
24 Finnish national screening for hypothyroidism. Few false positives, early
25 therapy. *Eur J Pediatr* 143:2-5.
26
27
28 21. Villar H, Saconato H, Valente O, Atallah A (2007) Thyroid hormone
29 replacement for subclinical hypothyroidism. *Cochrane Database Syst Rev*
30 CD003419.
31
32
33 22. Fish L, Schwartz H, Cavanaugh J, Steffes M, Bantle J, Oppenheimer J (1987)
34 Replacement dose, metabolism, and bioavailability of levothyroxine in the
35 treatment of hypothyroidism. Role of triiodothyronine in pituitary feedback in
36 humans. *N Engl J Med* 316:764-70.
37
38
39 23. Ross D, Daniels G, Gouveia D (1990) The use and limitations of a
40 chemiluminescent thyrotropin assay as a single thyroid function test in an out-
41 patient endocrine clinic. *J Clin Endocrinol Metab* 71:764-9.
42
43
44 24. Beardon P, McGilchrist M, McKendrick A, McDevitt D, MacDonald T (1993)
45 Primary non-compliance with prescribed medication in primary care. *BMJ*
46 307:846-8.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table captions:

Table 1 Number of cases and prevalence (per 100 persons in the year 2007) of levothyroxine-treated hypothyroidism by gender and age groups.

Table 2 Number of cases and one-year (in 2007) prevalence rates (%) of levothyroxine-treated hypothyroidism by university hospital district in Finland.

Table 3 Number of cases and one-year (in 2007) prevalence rates (%) of low levothyroxine daily dosage (<51 µg) users by university hospital district in Finland.

Table 1 Number of cases and prevalence (per 100 persons in the year 2007) of levothyroxine-treated hypothyroidism by gender and age groups.

	Female	Prevalence Rate	Male	Prevalence Rate	Gender
	N	(95% CI)	N	(95% CI)	Prevalence Rate Ratio
Age groups:					
– 19	1,792	0.29 (0.29–0.31)	729	0.12 (0.11–0.13)	2.6
20–29	4,789	1.48 (1.44–1.53)	880	0.26 (0.24–0.28)	5.7
30–39	9,979	3.15 (3.09–3.22)	1,687	0.51 (0.49–0.53)	6.2
40–49	19,058	5.16 (5.09–5.24)	3,595	0.95 (0.92–0.98)	5.4
50–59	34,173	8.63 (8.54–8.73)	6,148	1.56 (1.52–1.60)	5.5
60–69	37,741	12.11 (11.98–12.23)	7,292	2.52 (2.46–2.58)	4.8
70–79	31,151	13.99 (13.84–14.15)	6,499	3.92 (3.83–4.02)	3.6
80–	20,117	13.64 (13.45–13.83)	3,397	5.16 (4.99–5.33)	2.6
All	158,800	5.91 (5.88–5.94)	30,227	1.17 (1.15–1.18)	4.5*

* adjusted for age

Table 2 Number of cases and one-year (in 2007) prevalence rates (%) of levothyroxine-treated hypothyroidism by university hospital district in Finland.

	Number * of patients	Population at risk	Prevalence rate %	95% CI
University hospital area:				
Turku	31,064	713,071	4.36	(4.31–4.41)
Oulu	28,535	726,883	3.93	(3.88–3.97)
Kuopio	30,763	846,716	3.63	(3.59–3.67)
Tampere	43,011	1,208,581	3.56	(3.53–3.59)
Helsinki	55,549	1,780,267	3.12	(3.09–3.15)
The entire country	189,027	5,275,518	3.58	(3.57–3.60)

* residence unknown of 105 cases

Table 3 Number of cases and one-year (in 2007) prevalence rates (%) of low levothyroxine daily dosage (<51 µg) users by university hospital district in Finland.

	Number * of patients	Population at risk	Prevalence rate %	95% CI
University hospital area:				
Turku	4,444	713,071	0.62	(0.61–0.64)
Oulu	4,319	726,883	0.59	(0.58–0.61)
Kuopio	3,444	846,716	0.41	(0.39–0.42)
Tampere	5,481	1,208,581	0.45	(0.44–0.47)
Helsinki	8,522	1,780,267	0.48	(0.47–0.49)
The entire country	26,219	5,275,518	0.50	(0.49–0.50)

* residence unknown of 9 cases

Figure caption:

Fig. 1 Mean daily dosages (µg /d) of levothyroxine treatment during 2007 by gender and age groups.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Peer Review